Protalix BioTherapeutics Inc (PLX) Implied Volatility Current

Tracking PLX implied volatility helps you identify when options premiums on Protalix BioTherapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Protalix BioTherapeutics Inc implied volatility reflects the market's expectation of future price movement: when PLX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Protalix BioTherapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For PLX, tracking metrics like PLX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on PLX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases.

The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where PLX implied volatility sits today versus where it has been. Our scanner ranks Protalix BioTherapeutics Inc implied volatility against its historical range, surfaces extremes in PLX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Protalix BioTherapeutics Inc IV is rich or cheap — measure it, then act on it.